EP Patent

EP2630146A1 — Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt

Assigned to Medivation Technologies LLC · Expires 2013-08-28 · 13y expired

What this patent protects

Provided herein are (8 S , 9 R )-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-lH-1,2,4-triazol-5- yl)-8,9-dihydro-2 H -pyrido[4,3,2- de ]phthalazin-3(7 H )-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a …

USPTO Abstract

Provided herein are (8 S , 9 R )-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-lH-1,2,4-triazol-5- yl)-8,9-dihydro-2 H -pyrido[4,3,2- de ]phthalazin-3(7 H )-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8 S ,9 R )-5-fiuoro-8-(4-fluorophenyl)-9-(1-methyl-1 H -1,2,4-triazol-5-yl)-8,9-dihydro-2 H - pyrido[4,3,2- de ]phthalazin-3(7 H )-one tosylate salt are also provided, as are methods of using (8 S ,9 R )-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1 H -1,2,4-triazol-5-yl)-8,9-dihydro-2 H - pyrido[4,3,2- de ]phthalazin-3(7 H )-one tosylate salt to treat a disease or condition, such as a cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2630146A1
Jurisdiction
EP
Classification
—
Expires
2013-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Medivation Technologies LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.